Abstract
Background/Aims
The aim of this study was to elucidate the antiviral efficacy and the predictors of entecavir treatment in nucleoside-naive chronic hepatitis B patients. Methods: A total of 160 patients treated with entecavir (0.5 mg daily) for at least 24 weeks were consecutively enrolled. The virologic response (HBV DNA<2,000 copies/mL), biochemical response (ALT≤ upper limit of normal), and virologic breakthrough (>1 log10 copies/mL increase in HBV DNA level above nadir on two consecutive occasions) were retrospectively analyzed. Results: The mean follow-up duration was 58.8 weeks, and 85 patients (53.1%) showed HBeAg positivity. The median pretreatment levels of serum ALT and HBV DNA were 99 IU/L and 7.6 log10 copies/mL, respectively. The cumulative rates at 12, 24, 48, and 72 weeks were 37.5%, 68.1%, 87.4%, and 95.8%, respectively, for the virologic response; 40.0%, 66.2%, 84.5%, and 92.7% for the biochemical response; 10.6%, 18.8%, 27.0%, and 34.5% for HBeAg loss; and 3.5%, 7.1%, 9.0%, and 13.2% for HBeAg seroconversion. There was no case of virologic breakthrough. An absence of HBeAg and a low serum HBV DNA level (<8 log10 copies/mL) at baseline were significant predictors of the virologic response in a multivariate analysis (P<0.01). Conclusions: Entecavir therapy showed excellent efficacy in nucleoside-na?ve chronic hepatitis B patients. The predictors of a virologic response were an absence of HBeAg and a low baseline HBV DNA level. (Korean J Hepatol 2010;16:57-65)
Citations
Citations to this article as recorded by
- Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B
T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk, N. L. Bondarenko
Experimental and Clinical Gastroenterology.2023; (4): 77. CrossRef - A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients
Bircan Kayaaslan, Esragul Akinci, Alpay Ari, Zeliha Kocak Tufan, Saygın Nayman Alpat, Ozgur Gunal, Selma Tosun, Rahmet Guner, Fehmi Tabak
Clinics and Research in Hepatology and Gastroenterology.2018; 42(1): 40. CrossRef - Role of Plasma Osteopontin Level as a Predictor of Hepatic Fibrosis Regression and Response to Antiviral Treatment in Patients with Chronic HBV or Chronic HCV Infection
Heba A. Osman, Ali A. Ghweil, Ashraf Khodeary
Open Journal of Gastroenterology.2018; 08(12): 434. CrossRef - Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh
Clinical and Molecular Hepatology.2017; 23(4): 331. CrossRef - Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study
Ayse Batirel, Ertugrul Guclu, Ferhat Arslan, Funda Kocak, Oguz Karabay, Serdar Ozer, Munevver Turanli, Ali Mert
International Journal of Infectious Diseases.2014; 28: 153. CrossRef - Effect of Entecavir in Patients Who Lack Lamivudine Resistance after Lamivudine Treatment for Chronic Hepatitis B
Kyung Ho Ha, Dong Wook Joo, Ji Suk Kim, Byung Seok Kim, Chang Hyeong Lee
Korean Journal of Medicine.2013; 84(6): 810. CrossRef - Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B
T.-T. Zhang, J. Ye, S.-L. Xia, Y.-F. Zhang, Q. Su, Z.-H. Zhang, X. Li
Infection.2013; 41(2): 371. CrossRef - Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection
Won Gil Chung, Hong Joo Kim, Young Gil Choe, Hyo Sun Seok, Chang Wook Chon, Yong Kyun Cho, Byung Ik Kim, Young Yool Koh
Clinical and Molecular Hepatology.2012; 18(2): 195. CrossRef - Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
Joon Chang Song, Bo Young Min, Jin-Wook Kim, Jong Yeop Kim, Yeo Myeong Kim, Cheol Min Shin, Sang Hyub Lee, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee
The Korean Journal of Hepatology.2011; 17(4): 268. CrossRef - Predictors for virologic response in management of chronic hepatitis B
Jung Min Lee, Sang Hoon Ahn
The Korean Journal of Hepatology.2010; 16(1): 1. CrossRef
